NCT06727136View on ClinicalTrials.gov

A Study to Characterize Single and Repeat Dose Pharmacokinetics of Tebipenem-Pivoxil-Hydrobromide (TBP-PI-HBr) and Its Major Metabolite (SPR1349) in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

November 20, 2024

Primary Completion Date

April 22, 2025

Study Completion Date

April 22, 2025

Conditions
Healthy Participants
Interventions
DRUG

TBP-PI-HBr

TBP-PI-HBr film-coated immediate-release tablets

Trial Locations (1)

84124

Medical Facility, Salt Lake City, Salt Lake City

Sponsors

Lead Sponsor

Spero Therapeutics

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Spero Therapeutics

INDUSTRY

NCT06727136 - A Study to Characterize Single and Repeat Dose Pharmacokinetics of Tebipenem-Pivoxil-Hydrobromide (TBP-PI-HBr) and Its Major Metabolite (SPR1349) in Healthy Participants | Biotech Hunter | Biotech Hunter